<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01864187</url>
  </required_header>
  <id_info>
    <org_study_id>Morbid Obesity</org_study_id>
    <nct_id>NCT01864187</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dexmedetomidine in Morbid Obesity</brief_title>
  <official_title>A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine hydrochloride ,a relatively new drug in Chinais ,is a highly selective,
      potent a2-adrenoceptor agonist with significant analgesic, sedative and anxiolytic effects.
      The morbid obesity in Chinese population is rapidly increasing. But the pharmacokinetics of
      the drug in these people is still unknown.This research was designed to study the
      pharmacokinetics of dexmedetomidine in Chinese morbidly obese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the obese are sensitive to the disease such as hypertension, ischaemic heart disease and
      diabetes, the changes of the state may affect the pharmacokinetics of dexmedetomidine.
      Besides,the clearance of dexmedetomidine is parallel with liver function and it is excreted
      by kidney, so differences in the obese may be expected.

      About 10 obese patients and 10 matched healthy volunteers with normal weight would be chosen
      to receive a normal dosage of dexmedetomidine. And venous samples will be collected in
      different time points. Next the investigators can get the plasma concentration of
      dexmedetomidine by the use of HPLC-MS. And then the plasma concentration could be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of dexmedetomidine</measure>
    <time_frame>0, 5, 10, 15, 20, 25, 30, 45 , 60, 90, 120, 150,180,240,360,480 hours post‐dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each team will be administered for 1μg/kg of dexmedetomidine eace one.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Weight:28≦BMI≦45 and 18.5≦BMI≦24

          2. Written informed consent from the patient or the relatives of the participating
             patient.

        Exclusion Criteria:

          1. A previous history of intolerance to the study drug or related compounds and
             additives.

          2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>bo xu</last_name>
    <phone>88653387</phone>
    <phone_ext>020</phone_ext>
    <email>xubo333@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangzhou Military Region General Hospital, Department of Anesthesiology</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Zhi Li</last_name>
      <phone>15625052815</phone>
      <phone_ext>86</phone_ext>
      <email>lytow@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Iirola T, Aantaa R, Laitio R, Kentala E, Lahtinen M, Wighton A, Garratt C, Ahtola-Sätilä T, Olkkola KT. Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Crit Care. 2011;15(5):R257. doi: 10.1186/cc10518. Epub 2011 Oct 26.</citation>
    <PMID>22030215</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>bo xu</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

